ZVRA vs. EOLS, AUPH, PRAX, WVE, ETNB, NRIX, NUVB, PLRX, STOK, and GHRS
Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Evolus (EOLS), Aurinia Pharmaceuticals (AUPH), Praxis Precision Medicines (PRAX), Wave Life Sciences (WVE), 89bio (ETNB), Nurix Therapeutics (NRIX), Nuvation Bio (NUVB), Pliant Therapeutics (PLRX), Stoke Therapeutics (STOK), and GH Research (GHRS). These companies are all part of the "pharmaceutical preparations" industry.
Zevra Therapeutics (NASDAQ:ZVRA) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, community ranking, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
In the previous week, Zevra Therapeutics and Zevra Therapeutics both had 3 articles in the media. Evolus' average media sentiment score of 1.58 beat Zevra Therapeutics' score of 1.30 indicating that Evolus is being referred to more favorably in the news media.
Zevra Therapeutics currently has a consensus price target of $19.50, suggesting a potential upside of 319.35%. Evolus has a consensus price target of $21.25, suggesting a potential upside of 64.35%. Given Zevra Therapeutics' higher probable upside, research analysts clearly believe Zevra Therapeutics is more favorable than Evolus.
Zevra Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.
Evolus has a net margin of -27.31% compared to Zevra Therapeutics' net margin of -181.76%. Evolus' return on equity of 0.00% beat Zevra Therapeutics' return on equity.
Zevra Therapeutics has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.
35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 6.1% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Evolus received 329 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 72.00% of users gave Evolus an outperform vote.
Summary
Evolus beats Zevra Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Zevra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevra Therapeutics Competitors List
Related Companies and Tools
